GlassScriptPhysician profile
Amy W Hamilton
NPI 1205879210
$3,305.75
in general payments reported to CMS, 2019-2025
28 companies · $946 in 2025
The $946 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $642 · 2022: $416 · 2023: $307 · 2024: $994 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $661.86 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.02 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $408.30 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $339.34 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $196.96 | 2021-2025 | |
| Amgen INC. | $175.67 | 2025 | Evenity, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $162.63 | 2021-2025 | Trintellix |
| Exact Sciences Corporation | $145.72 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $71.35 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $68.04 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.69 | 2021-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $57.07 | 2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $49.98 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $46.98 | 2024 | Horizant |
| Abbott Laboratories | $39.32 | 2022-2024 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $38.26 | 2021 | |
| Organon LLC | $31.88 | 2024 | |
| Eisai INC. | $31.44 | 2021 | |
| Sanofi-Aventis U.S. LLC | $30.57 | 2021-2022 | |
| Ibsa Pharma INC. | $30.45 | 2021-2024 | Licart, Tirosint |
| Biohaven Pharmaceutical Holding Company LTD. | $28.98 | 2022 | |
| Currax Pharmaceuticals LLC | $28.16 | 2024 | Contrave |
| Teva Pharmaceuticals USA, INC. | $26.63 | 2022 | |
| Inspire Medical Systems, INC. | $25.42 | 2025 | Inspire |
| Seqirus USA INC | $21.61 | 2024 | Fluad, Flucelvax |
| Alk-Abello, INC | $17.30 | 2023 | Grastek, Odactra |
| Dexcom, INC. | $14.12 | 2023 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $9.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.